Dashboard
1
Poor Management Efficiency with a low ROCE of 3.56%
- The company has been able to generate a Return on Capital Employed (avg) of 3.56% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 10.34% and Operating profit at -18.44% over the last 5 years
3
With ROE of 2.95%, it has a expensive valuation with a 2.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,547 Million (Small Cap)
79.00
NA
1.17%
0.11
3.03%
2.47
Revenue and Profits:
Net Sales:
266 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.18%
0%
3.18%
6 Months
2.1%
0%
2.1%
1 Year
10.4%
0%
10.4%
2 Years
90.23%
0%
90.23%
3 Years
-5.81%
0%
-5.81%
4 Years
-62.1%
0%
-62.1%
5 Years
-23.86%
0%
-23.86%
Zhejiang Canaan Technology Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.34%
EBIT Growth (5y)
-18.44%
EBIT to Interest (avg)
1.65
Debt to EBITDA (avg)
0.80
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.79
Tax Ratio
11.27%
Dividend Payout Ratio
82.30%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.56%
ROE (avg)
3.60%
Valuation key factors
Factor
Value
P/E Ratio
79
Industry P/E
Price to Book Value
2.33
EV to EBIT
88.26
EV to EBITDA
28.36
EV to Capital Employed
2.15
EV to Sales
1.86
PEG Ratio
0.41
Dividend Yield
1.24%
ROCE (Latest)
2.44%
ROE (Latest)
2.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
265.70
297.80
-10.78%
Operating Profit (PBDIT) excl Other Income
-4.50
9.70
-146.39%
Interest
4.60
3.40
35.29%
Exceptional Items
0.50
0.00
Consolidate Net Profit
-0.30
-1.70
82.35%
Operating Profit Margin (Excl OI)
-17.00%
-12.50%
-0.45%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -10.78% vs 3.37% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 82.35% vs -115.89% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,378.60
1,043.90
32.06%
Operating Profit (PBDIT) excl Other Income
96.30
12.00
702.50%
Interest
15.80
7.30
116.44%
Exceptional Items
1.60
0.10
1,500.00%
Consolidate Net Profit
30.40
-27.90
208.96%
Operating Profit Margin (Excl OI)
30.60%
-34.10%
6.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 32.06% vs -4.96% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 208.96% vs 66.55% in Dec 2023
About Zhejiang Canaan Technology Ltd. 
Zhejiang Canaan Technology Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






